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Abstract
Background: Protein Kinases are a superfamily of proteins involved in crucial cellular processes such as cell cycle
regulation and signal transduction. Accordingly, they play an important role in cancer biology. To contribute to the
study of the relation between kinases and disease we compared pathogenic mutations to neutral mutations as an
extension to our previous analysis of cancer somatic mutations. First, we analyzed native and mutant proteins in
terms of amino acid composition. Secondly, mutations were characterized according to their potential structural
effects and finally, we assessed the location of the different classes of polymorphisms with respect to kinase-
relevant positions in terms of subfamily specificity, conservation, accessibility and functional sites.
Results: Pathogenic Protein Kinase mutations perturb essential aspects of protein function, including disruption of
substrate binding and/or effector recognition at family-specific positions. Interestingly these mutations in Protein
Kinases display a tendency to avoid structurally relevant positions, what represents a significant difference with
respect to the average distribution of pathogenic mutations in other protein families.
Conclusions: Disease-associated mutations display sound differences with respect to neutral mutations: several
amino acids are specific of each mutation type, different structural properties characterize each class and the
distribution of pathogenic mutations within the consensus structure of the Protein Kinase domain is substantially
different to that for non-pathogenic mutations. This preferential distribution confirms previous observations about
the functional and structural distribution of the controversial cancer driver and passenger somatic mutations and
their use as a proxy for the study of the involvement of somatic mutations in cancer development.
Background
Point mutations of nucleotide bases are a mechanism of
crucial importance in the evolution of proteins, and
hence in the evolution of organisms. A biologically rele-
vant class of point mutation, accounting for about 90%
of sequence polymorphisms [1] at an overall frequency
of about one per 1000 bases [2] is the single nucleotide
point mutation or PM. Traditionally, polymorphisms are
classified according to their genomic location into cod-
ing or non-coding. Coding PMs can be further classified
depending on whether the resulting protein product is
changed owing to the genomic polymorphism. Non-
synonymous PMs (nsPMs) are those that alter the
amino acid sequence of the protein product through
either amino acid substitution or the insertion of trun-
cation mutations. We refer to those which generate a
single amino acid substitution as ‘single amino acid
polymorphisms’ or SAAPs. In contrast, synonymous
PMs (also referred as silent or sPM) are those that do
not alter the amino acid sequence of the protein pro-
duct expressed. A particular case of PMs corresponds to
single nucleotide polymorphisms (SNPs): those germline
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mutations frequently found (>1%) in normal individuals
and considered neutral. A major effort to catalogue and
annotate SNPs is dbSNP [3]. Although most amino acid
changes are tolerated in the native protein structure, not
all PMs are neutral. An increasing number of mutations
are prone to be associated with aberrant phenotypes and
disease. Disease-associated mutations occur at much
lower frequencies in the population and have a severe
effect on phenotype. Here, we use the term ‘pathogenic
deviation’ (PD hereafter) to refer to any single base
change reported to be correlated with disease. Although
both PDs and nsSNPs result in a change in the
expressed protein product, the former are reported to
have a severe effect on phenotype whereas nsSNPs are
expected to have a non-deleterious phenotypic effect.
About 1% of all human genes are known to contribute
to cancer as a result of acquired mutations. The family
of genes most frequently contributing to cancer is the
Protein Kinase gene family [4] which is implicated in a
huge number of tumorigenic functions including
immune evasion, proliferation, antiapoptotic activity,
metastasis and angiogenesis, possibly due to the simpli-
city of the mechanism of attaching an ATP-derived
phosphate to a substrate protein [5]. Protein Kinases are
one of the most ubiquitous families of signaling mole-
cules in the human cell, accounting for approximately
2% of the proteins encoded by the human genome [6].
Protein Kinases show a wide-scale similarity both at
sequence and structure level, attributable to the fact that
all kinases transfer the terminal phosphate of ATP to a
serine, threonine or tyrosine residue in a target protein.
Empirical studies to date also suggest a common, with a
few exceptions, catalytic mechanism whereby ATP and
an active site divalent cation are bound in identical
manners and phospho-transfer is carried out by a shared
set of amino acids [7]. Studies [8,9] on yeast models
have shown that kinases can be very promiscuous, phos-
phorylating a huge number of different protein sub-
strates albeit showing remarkable specificity. This
inconsistency suggests that kinases have a region com-
mitted to the general function of catalysis, with another
region (or regions) customizable to confirm substrate
specificity to the enzyme without any particular need to
alter fold, compromise ligand binding or modify the
subsequent reaction mechanism. Protein Kinases are a
thoroughly studied protein family and a plethora of
mutations have been previously reported in the litera-
ture [10]. These studies often include evidence of asso-
ciation with disease. Concomitantly, several efforts
[11,12] are devoted to the prediction of the pathogeni-
city of somatic kinase mutations in cancer samples.
These mutations are classified into two main categories:
those that are involved in cancer onset and development
–driver mutations– and those that are biologically
neutral –passenger– mutations. For a detailed review,
see Baudot et al.,2009 [13]. Previous work [14] charac-
terized the preferential distribution of cancer driver
kinase somatic mutations in regions of importance for
protein function, including disruption of substrate bind-
ing and/or effector recognition at family-specific posi-
tions, often avoiding structurally relevant positions.
The objectives of the work presented here are two-
fold. Firstly, we wanted to clarify whether the trends
detected for driver somatic kinase mutations can be
extended to other disease related mutations indepen-
dently of the nature of the mutation. Secondly, we
wanted to provide additional information to the discus-
sion on the interpretation of the role of kinase driver
somatic mutations in the onset of cancer.
Consequently, we carried out a detailed multi-level
comparative analysis of the differences between patho-
genic and neutral (not pathogenic) germline mutations
within the framework of the human kinome: amino acid
composition of the polymorphisms was compared,
mutations were characterized according to their poten-
tial structural effects and finally, we assessed the loca-
tion of the different classes of polymorphisms with
respect to kinase-relevant positions in terms of subfam-
ily specificity, conservation, accessibility and functional
sites.
Results and discussion
Sequence features of deleterious kinase mutations
We mapped 130 pathogenic deviations and 200 neutral
SNPs to sequences within the Protein Kinase domain
(PDPKs and SNPPKs, respectively). The native residue in
the pathogenic (PDPK) set was enriched in glycines
(p=0.01) and leucines (p=0.04) when the sequences were
compared using a two-sided Fisher exact test whereas it
was enriched in prolines (p=3x10–5) when the mutant
amino acids were considered. As expected, in the SNPPK
dataset none of the residue types were particularly
enriched, neither in the native sequences nor in the
mutated ones. Considering the native and mutant as a
residue pair, three mutations were found more often in
the PDPK dataset: leucine-proline (p=0), lysine-glutamate
(p=0.02) and arginine-proline (p=0.02). Again, in the
SNPPK dataset, no significant enrichment was found for
the the wildtype-mutated pairs. The complete set of
results can be found in Supplementary Table S2 in
Additional file 1.
Hypothesized structural effects of deleterious kinase
mutations
SAAPdb [15] provides a characterization of the struc-
tural consequences of mutations. When these features
were compared some differences between the groups
appeared. PDPKs were often observed at the interface
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(p=0.03) including sites of inter-chain binding, as well as
ligand binding. By contrast, SNPPKs significantly
(p=0.04) more often than PDPKs tend to create empty
spaces in the protein as a consequence of the difference
in volume introduced by the side chain change, either in
the core of the protein or in partially buried regions.
Protein Kinase pathogenic mutations (PDPK) compared
to pathogenic mutations outside this domain (PDnPK,
standing for ’non protein kinase’) produced striking
results: PDnPKs were more often explained by structural
analyses: the modified residues affected stability, affected
functional residues, introduced an empty region in the
interior of the protein, and affected interaction prone
positions (as annotated in MMDBBIND). By contrast,
PDPK mutations were not significantly related with any
of those categories. A complete description of these
results can be found in Supplementary Table S3 in
Additional file 1.
Proximity of deleterious kinase mutations to kinase-
specific protein features
We present here the results of mapping the different
types of mutations, PDPKs and SNPPKs, onto a repre-
sentative structural model from the Protein Kinase
superfamily. The mutations were analyzed in terms of
their distribution relative to evolutionary conserved
positions and known functional regions. We were able
to map 47 positions containing at least one of the 62
PDPK mutations and 27 positions with at least one of
the 36 SNPPKs to the consensus model (Figure 1)
described in the Methods section and in previous stu-
dies [14]. The results of these analyses are summarized
in Table 1.
Proximity of kinase mutations to known functional regions
a) Kinase mutations and the catalytic region The
active region of Protein Kinases includes the ATP bind-
ing site, the peptide-substrate binding sites and the cata-
lytic loop implicated in the transference of the
phosphate group. We defined the kinase-binding site as
the set of residues extracted from the FireDB database
[16]. This definition includes 32 residues (Figure 1) that
directly contact the ATP in the binding pocket and that
contains the five highly conserved residues that play a
critical role in positioning ATP and stabilizing the active
conformation in the catalytic mechanism [7] (see Figure
1). The distance distribution histograms (Figure 2,
panels A and B) and the results in Table 1 (see also Fig-
ure S2 in Additional file 1, where the PDPKs, SNPPKs
and catalytic residues were represented), showed a very
strong tendency of PDPKs to locate if not in catalytic
residues, at least close to them. Indeed, 13 out of the 32
residues in the binding pocket were annotated as patho-
genic whereas only three were annotated as neutral.
Moreover, 2 out of the 5 residues described as essential
Figure 1 Consensus model structure of summarizing the
human Protein Kinase family The model structure of human
Protein Kinase, based on MAP3K1, shows the basic two-lobe kinase
fold, with the N- and C-terminal (green and orange respectively)
lobes joined by a hinge region (magenta). Substrate recognition is
through interaction with the activation segment (blue), a region in
the C-terminal lobe. The substrate-binding groove is located
between the catalytic loop, the P+1 loop (activation segment), helix
D, helix F, helix G and helix H. ATP binds at a site between the two
lobes (yellow) that includes five conserved residues: (i) Lysine 74
that interacts with the alpha and beta phosphates of ATP and
thereby stabilizing it; (ii) a nearby glutamic acid (E96) forms a salt
bridge with lysine 74 increasing the stabilization network; (iii)
Aspartate 171 is the catalytic base that initiates phosphotransfer by
deprotonating the acceptor serine, threonine or tyrosine; (iv)
Asparagine 176 interacts with a secondary divalent cation, thereby
positioning the gamma-phosphate of ATP, and finally (v) Aspartate
190 which chelates the primary divalent cation, indirectly
positioning ATP at the same time.
Table 1 Results of the Xd analysis comparing PDPKs and
SNPPKs
Feature PD (Å) SNP (Å) ΔXd
Conservation - Shannon 7.17 6.71 -0.13
Conservation - AL2CO 8.49 10.49 -0.52
Structural Conservation 7.56 7.00 2.10
Accessibility - Buried 2.94 3.63 -0.83
Catalytic - FireDB 8.69 12.66 -4.74
Catalytic - Knight 11.89 16.26 -2.33
TreeDeterminants 6.00 7.94 -1.98
Where PD (Å) and SNP (Å) stand for the average closest distances in
Angstroms from the feature residue and the PDs and SNPs respectively, and
ΔXd for the difference in Xd values. Negative values indicate that the PDs are
closer to the feature residues whereas positive values indicate that SNPs are
in the surroundings of feature residues.
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for the correct functioning of the ATP binding pocket
[7] were annotated as PDPKs.
b) Kinase mutations and regions of functional sub-
specificity In this study we used the position of the
tree-determinant residues as a proxy for functionally
important regions in Protein Kinases, particularly those
related with the specific functions of each one of the
subfamilies. Residues specific to the various subfamilies
of Protein Kinases were identified for each of the eight
subfamilies in which KinBase categorizes the human
kinome [6]. Our recent implementation of the
sequence-space approach, S3det [17] identified 32
unique positions in the model as containing information
relevant for differentiating between subfamilies; that is,
residues that tend to be conserved in the specific subfa-
milies and vary to different degrees in the others (Fig.
S3 in Additional file 1 depicts the distribution of the
mutations along with these tree-determinant residues).
Out of the 32 tree-determinants in the model, five were
annotated as pathogenic (residues 50, 173, 190, 217 and
233 in the generated structural model) whereas only two
were annotated as neutral. Pathogenic deviations, if not
exactly in positions that were disease-associated, clus-
tered around tree-determinant residues in general. This
tendency was especially relevant for tree-determinants
in the ATP binding pocket, but also appreciable in the
other function specific tree-determinants. PDPKs were
closer to tree-determinant positions than neutral
SNPPKs (Fig. 2C) This was also clear in the difference of
Xd values (-1.98) indicating the existence of significant
differences between PDPKs and SNPPKs with respect to
proximity to positions characterized as important for
the function and subspecificity of the kinases.
Proximity of kinase mutations to the protein core
With the accessibility parameters defined in Methods,
99 residues were classified as buried in the kinase struc-
tural model; 20 of these buried residues are annotated
as PDPKs and 12 were annotated as SNPPKs (three resi-
dues – 58, 197 and 218 – are described in both data-
sets) (Fig. S4 in Additional file 1). The distribution of
distances (Fig. 2D) manifests a clear tendency of PDPKs
to be closer to buried residues. As a matter of fact, the
analysis of the mean distances of mutated positions to
buried residues (2.94Å and 3.63Å respectively) revealed
a tendency for the pathogenic deviations (PDPKs) to be
closer to buried residues than the neutral polymorph-
isms. This fact was supported by a Xd difference of
-0.83.
Examples of well-characterized disease-associated
mutations affecting kinase function
The statistically significant results provided after analyz-
ing the sequence features of the single amino acid poly-
morphisms (see sequence features of deleterious kinase
mutations section) are supported by several examples in
the literature. Karkkainen et al., (2000) [18] associated
human hereditary lymphedema, a particular case of lym-
phatic obstruction, with mutations in the vascular
Figure 2 Histograms of the distribution of distances between
mutated resides and the analyzed features. (A) Catalytic residues
according to FireDB. (B) Catalytic Residues according to Knight et al
(2007). (C) Tree-Determinants (D) Buried residues.
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endothelial growth factor receptor 3 (VEGFR-3). The
endothelial cells lining blood and lymphatic vessels
depend on signal transduction mediated by specific
receptor tyrosine kinases for their differentiation into a
primary vascular plexus (vasculogenesis) and for the
sprouting and splitting of new capillaries from pre-
viously existing vessels (angiogenesis). Two mutations
were reported as the cause of the disease, due to the
loss of tyrosine kinase activity and hence impaired
downstream signaling, and a slower rate of internaliza-
tion of the receptor. The suggested model highlights a
mutation in the second arginine in the highly conserved
HRDLAARN motif in the catalytic site to proline that
facilitates the hydrogen bond between aspartate and a
hydroxyl group from ATP at the binding pocket. This
aspartate is critical for protein function as it is believed
to act as the catalytic base in the phosphotransfer reac-
tion. Moreover, their study revealed that a mutation
from leucine to proline disturbed protein function due
to both a disturbance in protein structural integrity and
an interference of ATP binding. Since the pathogenic
residue is located in the middle of a b-strand, introdu-
cing a restricted mobility residue such as proline dis-
rupts the interaction with the surrounding b-strands,
destabilizing the protein fold in the region. In addition,
the sidechain of this leucine is part of the adenine-bind-
ing pocket, therefore alterations in such a relevant posi-
tion modify the shape of the cleft and might interfere
with ATP binding. With respect to the significant
lysine-glutamate mutation, Mao et al., (2001) [19]
described the commonly cited mutation K430E
(amongst others) in Bruton’s tyrosine kinase (BTK,
Q06187), speculating with regard to how it might cause
severe XLA (X-linked agammaglobulinemia), and pro-
viding a solved crystal structure. BTK is expressed on
the surface of B cells and its kinase activity is crucial in
proliferation and differentiation to mature B lympho-
cytes. According to their mechanism, upon the trans-
phosphorylation of Y551, the highly conserved K430
facilitates a hydrogen bond with E445, causing a shift of
the aC helix. The K430E mutation disables the aC helix
repositioning, which is crucial for the catalytic activity
of BTK, hence impairing the creation of mature B cells.
Assessing the possible functional role of relevant kinase
mutations by their sequence-structure characteristics
Our general analysis of the distribution of mutations in
Protein Kinases not only provided an overview of their
relation with function and structure, but also provided
an insight into their specific biomedical implications. In
the work presented here, we summarized all the knowl-
edge accumulated for the Protein Kinase domain in a
single framework structure (Fig. 1) under the assump-
tion that regions important for the structure/function of
the kinases are common to the whole family and hence
they can be used as a reference for the interpretation of
the mutations in any of the individual kinases. The
accumulation of information clearly increases the signifi-
cance of the results provided and makes the distribution
of the polymorphisms more reliable and accurate. For
instance, mutations in the insulin receptor gene in
humans (INSR) have been reported as disease-associated
in the literature. Defects in INSR are the cause of insu-
lin-resistant diabetes mellitus with acanthosis nigricans
type A (IRAN type A, MIM:610549), a syndrome char-
acterized by the association of severe insulin resistance
manifested by marked hyperinsulinemia and a failure to
respond to exogenous insulin with the skin lesion
acanthosis nigricans and overian hyperandrogenism in
adolescent female patients. The relation of the disease
with mutations in kinases is thoroughly reported in
OMIM. Recent studies have further characterized the
relationship between insulin resistance and disease (for
example, [20]). Moreover, several studies have associated
acanthosis nigricans with mutations in other kinases,
such as the fibroblast growth factor receptors II and III
[21-23]. Here, we identified A1161T (residue 173 in the
model), a well-characterized mutation that introduces
an alanine-threonine shift in the ATP binding pocket of
INSR. This mutation has been defined in our analysis as
a pathogenic deviation (PDPK). Concomitantly, it is a
catalytic residue in FireDB and is important for family
specificity. This perturbation of the ATP binding pocket
might explain the unpaired phosphorylation and there-
fore the reduced enzymatic activity leading to the aber-
rant phenotype.
Finally, we considered not only a single mutation but
a pair of consecutive mutations: T341P and C342F
(positions 233 and 234 in the structural model respec-
tively), in the human fibroblast growth factor receptor
type 2 (FGFR2) to demonstrate that although only
T341P is reported to be a pathogenic deviation in our
dataset, the analysis can provide insights into complex
diseases caused by more than one mutation at the same
time. Several diseases caused by uncontrolled cell
growth have been associated to defects on FGFR2.
Among them, two related syndromes – Pfeiffer syn-
drome (PS) and Crouzon syndrome (CS) – have been
reported to be associated to the pair of mutations of
interest (T341P in PS and CS, C342F in CS). In our ana-
lysis, we described T341P as a mutation that introduces
a change from threonine to proline in a buried
sequence-conserved position. Other authors [15,24] have
shown that mutations to proline are very often asso-
ciated with disease. Additionally, we have characterized
mutation C342F as a replacement of a buried residue. In
addition, we identified both mutations as tree-determi-
nant residues, thus considered related to binding
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specificity and indicative of the importance of these two
positions for protein function.
Conclusions
We have analyzed point mutations in the structure of
Protein Kinases in order to characterize the structural
and functional singularities of pathogenic and neutral
mutations. Although the definition of the groups is by
no means stable and the groups are constantly being
redefined as new studies on the pathogenicity of muta-
tions arise, this might be used as a proxy to deepen the
knowledge on the underlying mechanisms of disease.
The human kinome is particularly amenable for this
type of study since much is known about the structure
and function of this protein family and very relevant
cancer-associated mutations have been published for
these proteins [11,12,14].
To address this point, pathogenic deviations mapped
to the kinase domain (PDPK) and single nucleotide poly-
morphisms mapped to the kinase domain (SNPPK) were
compared on the basis of sequence, hypothesized struc-
tural effect and proximity to known kinase-specific fea-
tures within the framework of a modeled consensus
structure, representative of the whole superfamily. At
the sequence level, several mutations were differentially
observed in the PDPK and SNPPK datasets: the leucine-
proline mutation emerged as an interesting feature of
the PDPK dataset: it was identified both when analyzing
the native and mutant residues separately, and when
analyzing the mutation pairs, and it has been identified
as being indicative of disease elsewhere, both specifically
in a kinase disease dataset [24] and in wider, non-dis-
ease-specific datasets [15,25,26]. In addition, replacing
an arginine with a proline was more often observed in
the PDPK dataset. Again, this mutation has been
described as being associated both with diseases pre-
dicted to be related to mutations in kinases [24] and
across all other diseases [15,26]. Finally, replacing the
positive charge of Lysine with the bulkier, negatively
charged glutamic acid sidechain is identified in the
PDPK dataset. Unlike the well-characterized previous
mutations, this is a novel observation. These finding
provide evidence about the existence of distinctive dif-
ferences between the two types of mutations even at
such a coarse grain level as the amino acid composition.
In the second part of the analysis we focused on the
singularities of the mutations in structurally and func-
tionally relevant regions. Thus, we characterized PDPK
mutations in terms of their structural consequences by
comparing them to SNPPK mutations. PDPK mutations
were more likely to occur at the interface with ligands
and other protein chains and SNPPK mutations were
more likely to introduce a cavity in the protein core.
This is coherent with the previous publications
concluding that disease-associated mutations in kinases
often affect the site of ATP binding [16,18,19]. In addi-
tion, PDPK mutations were compared to other PD muta-
tions (PDnPK) to comment on the mechanisms by which
mutations in kinases might lead to disease. In general, it
is easier to explain PDnPKs in structural terms. Most
noticeably, very few PDPK mutations resulted in a signif-
icant cavity, an empty space, or affected protein stability
at all. An increasing body of literature attributes the
pathogenic nature of PDs to their destabilizing effect on
native protein structure [15,27-30]. The results here,
specific to the mutations in the Protein Kinase domain,
contradict this trend, indicating that the pathogenicity
of PDPKs could not be simply attributed to a decreased
stability of the resulting proteins. This might be
explained by the fact that Protein Kinases are known to
be a highly structurally conserved superfamily, while
varying significantly with respect to sequence; as such,
the structures must be tolerant to sequence variation.
Hence, considerable flexibility must exist within the pro-
tein structure to be robust to sequence diversity. It is
noticeable the relatively small number of structures
available, we are aware that the results will benefit from
a dedicated modelling pipeline, especially for very diver-
gent kinases differing from the canonical PK domain. By
contrast, a customized model for every single protein
would not only increment the complexity of the com-
parative analysis of distances but would also add some
uncertainties derived from the use of protein models.
In order to provide more detailed insight into the dis-
tinctive implication of pathogenic mutations in the disrup-
tion of protein function, we characterized the differences
between PDPKs and SNPPKs by their association to kinase-
specific functional and structural features. There were sig-
nificant differences between the two types of mutations in
terms of conservation, accessibility, distance to active/
binding site residues and distance to family specific bind-
ing sites. It is interesting to compare these results with the
ones previously obtained for driver/passenger mutations
in Protein Kinases [14] from the works by [11,12] that
constitute a subset of the many mutations stored in COS-
MIC [31]. Drivers are those mutations predicted to be
involved in cancer onset whereas passenger mutations are
those that are supposed to be accumulated during cancer
progression being neutral respect to the origin of the can-
cer. In the previous work, the main conclusion was that
driver mutations tended to be located near to important
residues such as sequence conserved positions, family spe-
cific regions and active/catalytic sites whereas passenger
mutations were located closer to structurally conserved
regions. The difference observed here for the set of PDPKs
and SNPPKs mimicked the one previously observed for dri-
ver and passenger mutations. Both datasets proved to be
non-redundant. Only 4 residues were common to both
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driver and pathogenic datasets, all of them in the human
B-raf proto-oncogene. The small overlap encountered is
consistent with the very different nature –germline and
somatic– of the mutations in each of the disease-prone
datasets. Thus, the new results presented here can be seen
as a confirmation of the functional/structural role of the
mutations that are more likely to be pathogenic (drivers
and PDs). Given that the definition of mutations as drivers
and passengers is somehow controversial (For a review,
see [13]), it is good to see that the current results could be
interpreted as an indirect support to the categorization of
mutations into drivers (disease-associated) and passengers
(disease-neutral) and their use as a proxy for the study of
the involvement of somatic mutations in cancer biology.
In summary, we have confirmed that the pathogenicity
of mutations within the Protein Kinase superfamily is
related to essential aspects of protein function, including
perturbation of substrate binding and recognition by
effectors at family-specific positions. As a matter of fact,
pathogenic deviations (PDPK) accumulate in key func-
tional regions whereas they seem to be absent from
structurally relevant positions. These observations rein-
force the idea that the pathogenicity of disease-asso-
ciated mutations can be attributed to a disruption of
native protein function while avoiding drastic changes
prone to disrupt the protein globally. This tendency was
not observed for neutral polymorphisms, which are
apparently less disruptive of protein function and tend
to be tolerated. Consequently, they are more often
found in normal individuals. However, it is clear that
further classification of the mutations in more specific
subgroups will be necessary to provide a deeper knowl-
edge on the mechanisms leading to disease. A typical
example would be the characterization of mutations into
a gain-of-function/loss-of-function on a large-scale.
The analysis presented here provides not only a char-
acterization of the mutations, but also in some cases
additional insight into the specific biomedical implica-
tions of the mutations. This type of approach will be
particularly useful as part of the bioinformatics platform
developed for the International Cancer Genome Consor-
tium and other cancer genome projects. The results dis-
cussed in this work are biologically sound not only
because they contribute to our understanding of the
role of mutations in disease, but also because they can
bee seen as a necessary step towards the development of
predictors of pathogenicity based on the combination of
the features analyzed here. Indeed, further development
of the idea presented here might naturally derive in a
classifier that making use of machine learning techni-
ques would be able to predict the pathogenicity of any
novel kinase mutation.
Moreover, although out of the scope of this work, the
methodology used to analyze the distribution of the
mutations in relation to a set of features can be applied to
other families. However, we see (as other authors in the
field [24]) advantages to the in-depth exploration of a
family with more information about sequence, structure
and mutations and for what it is feasible to obtain phyloge-
netic information to calculate subfamily specific sequence
features. It remains interesting to analyze other protein
families at a genome wide scale to corroborate to what
extend the results shown in this work can be generalized.
Methods
Protein Kinase domain sequences
The KinBase resource [6] is a repository of the currently
accepted classification of eukaryotic Protein Kinases. At
the moment of the analysis, KinBase contained 620
human protein sequences of which 516 were Protein
Kinases not defined as pseudogenes by the database
curators. Although it has been described that some
kinase pseudogenes are transcribed and even might have
a residual or scaffolding function [32] kinase pseudo-
genes were not considered in the analysis performed
here. KinBase does not map directly onto UniProtKB
[33]. The mapping was performed using a BlastP [34]
for each sequence against a custom database containing
all entries in UniProtKB annotated as Protein Kinase
domain for human. We were able to map 488 KinBase
identifiers to a valid UniProtKB entry, 474 of them
(97.13%) at sequence identity levels of at least 95%.
Classification of the mutations
SAAPdb [15] is a database of single amino acid poly-
morphisms (SAAPs) mapped to protein structure.
SAAPdb aims to provide likely structural effects of
mutations and identify differences in potential structural
consequences between neutral and pathogenic muta-
tions. The disease dataset is derived mostly from OMIM
[35] whereas the neutral dataset comes from dbSNP.
For the Protein Kinase domain of the 488 kinases in
SAAPdb contains 130 pathogenic deviations (PDPKs)
and 200 neutral polymorphisms (SNPPKs). Of these 130
PDPKs, 62 were successfully mapped to a residue in the
solved PDB structure. Similarly, of the 200 SNPPKs
mapped to sequence, 36 were mapped to a PDB struc-
ture (See Supplementary Table S1 in Additional file 1).
In order to create control datasets 9263 non-kinase PDs
(PDnPK) were retrieved from SAAPdb, out of them 4652
mapped to a structure. All three datasets contain only
unique, non-synonymous (missense) mutations. We
excluded nonsense and synonymous mutations because
these have a known, truncating effect or no effect on
the protein structure. A unique mutation was defined by
the combination of four parameters: UniProtKB acces-
sion number and sequence position, native amino acid
and mutated amino acid.
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Comparing mutations with respect to the native and/or
mutant residues
To compare the mutations with respect to their
sequence features, the native and mutant residues were
extracted from SAAPdb, as described above. Two-sided
Fisher exact tests were carried out since they allow
robust comparison of datasets of disparate sizes and
evaluation of contingency tables with empty cells.
Structural effects of mutations
The SAAPdb hypothesized structural effects are fully
described elsewhere [15] and are summarised briefly
below. (a) Mutations affecting stability: mutations on the
surface of proteins that replace a hydrophilic residue
with a hydrophobic residue are identified as introducing
unfavourable hydrophobicity on the surface. Similarly,
mutations in the core that replace a hydrophobic residue
with a hydrophilic residue are identified as introducing
unfavourable hydrophobicity in the core. Buried muta-
tions that create a charge shift are also identified. Using a
geometric analysis of PDB structures, SAAPdb identifies
mutations that affect potential disulphide bonds. Muta-
tions that introduce large cavities in the protein core or
that break hydrogen bonds are identified as well. (b)
Mutations affecting folding: unfavourable (with respect
to torsion angles) mutations from cis-proline, from gly-
cine and to proline are identified. Mutations that will
clash with existing residues are identified. (c) Mutations
to UniprotKB annotated residues: mutations at the site of
residues annotated by UniprotKB as functionally relevant.
(d) Mutations to binding residues: PDB structures are
analysed to identify residues binding to proteins, DNA or
small molecules. These data are augmented by data from
MMDBBIND. (e) Mutations disrupting the quaternary
structure (f) Mutations to sequence conserved residues.
In addition, we provide results for the summary analyses
categories of structurally explained (where at least one
structural explanation is true, i.e., any explanation apart
from the sequence conservation) and explained (where at
least one explanation is true). In order to compare the
mutations with respect to their structural effects, a binary
explanatory vector is calculated for each mutation and a
two-sided Fisher exact test was carried out.
Generation of a consensus model summarizing Protein
Kinase structures
A consensus model (Fig.1) of the basic structure of the
kinase domain was created. This consensus model
represents the average structure of a large number of
kinases widespread along the human kinome, and there-
fore it is useful to summarize global characteristics of
the structures. To build the model we first selected
MAP3K1 as a standard representative sequence of the
family from a manually curated multiple sequence
alignment of the human kinome constructed using the
alignment package MUSCLE [36]. The selected
sequence was submitted to Modeller [37] assembling
the models created using all those closely related tem-
plate PDBs structures returned from a BLAST search.
The predicted model has previously been used as a con-
sensus of the Protein Kinase domain [14]. Finally, muta-
tions were transferred from their own PDB coordinates
to the consensus model for comparison.
Calculation of important regions
Calculation of accessibility
NACCESS (Hubbard, unpublished) is a stand-alone pro-
gram that calculates accessible areas by rolling a probe
with van der Waals radius over the surface of the mole-
cule. A residue is defined as buried if 16% or less of the
residue’s surface is exposed to the probe. This is a com-
mon threshold [38] that ensures a reasonable number of
buried residues.
Definition of catalytic sites
The FireDB database [16] contains a comprehensive
curated set of substrate binding and catalytic residues,
extracted directly from the PDB [39] or from the Cataly-
tic Site Atlas [40]. FireDB binding residues for the var-
ious kinases were mapped into the general model using
the corresponding multiple structure alignments.
Prediction of Tree Determinant positions
S3det [17] is an algorithm for the detection of groups of
proteins within a family with potential functional speci-
ficities and to identify the residues that are characteristic
of that group. S3det is based on the simultaneous quan-
titative analysis of sequences and residues within a mul-
tiple sequence alignment on related multidimensional
spaces. Those residues associated with specific sequence
subfamilies tend to be determinants of functional speci-
ficity and are located in functional regions of protein
families, including substrate binding sites, functional
sites and protein interaction sites.
Xd analysis
To assess the significance of the proximity of different
sets of mutations to areas of the protein (buried, func-
tional, conserved, etc) we used the harmonic deviation,
Xd, measure introduced previously [41].
Xd
P P
d n
ic ia
ii
i n
=
−
⋅
=
=∑
1
(1)
Where n is the number of distance bins in the distri-
butions, di is the upper limit for each bin, Pic is the per-
centage of residues with distance between di and di-1
and Pia is the same percentage for all residues in the
protein. Defined this way, positive values of Xd indicate
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that the population of residues is shifted to smaller dis-
tances with respect to the population of all residues. In
practice we used a difference of Xd values of 0.75 to
indicate distributions of residues that are significantly
different regarding their proximity to previously defined
areas of the protein. This threshold – albeit arbitrary –
is based on manual inspection of previous results and
has been proved valid in a similar context [14].
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